French test of leftover tumor DNA in the blood after pancreatic cancer surgery
French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients
This will test whether a blood test for tumor DNA after surgery or after adjuvant chemotherapy can find pancreatic cancer patients at high risk of relapse.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 37 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Montpellier Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montpellier, Hérault) |
| Trial ID | NCT06287749 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational project within the European GUIDE.MRD effort to confirm that circulating tumor DNA (ctDNA) after curative‑intent treatment indicates minimal residual disease in pancreatic ductal adenocarcinoma (PDAC). Adults with resectable PDAC scheduled for curative surgery at CHU de Montpellier will be enrolled and provide serial blood samples (liquid biopsies) after surgery and after adjuvant chemotherapy. Standardized ctDNA assays developed by the consortium will be used to determine ctDNA detection status and those results will be correlated with disease‑free survival and recurrence timing. The goal is to harmonize ctDNA testing methods and produce clinically useful data to guide follow‑up and treatment decisions.
Who should consider this trial
Good fit: Adults with confirmed resectable pancreatic ductal adenocarcinoma who are scheduled for curative‑intent surgical resection and can provide informed consent.
Not a fit: Patients with verified distant metastases, hereditary pancreatic cancer, or those unable to comply with follow‑up visits are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, it could help doctors identify patients with remaining cancer earlier so follow‑up and treatment can be better personalized.
How similar studies have performed: Prior smaller studies have found that post‑surgery ctDNA often predicts recurrence in pancreatic cancer, but prospective, standardized validation is still limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pancreatic ductal adenocarcinoma, according to the assessment of the MDT. * Age 18 years or older. * Scheduled for curative intent surgical resection. Exclusion Criteria: * Hereditary pancreatic cancer. * Verified distant metastases. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study. * Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening. * Pregnant or nursing woman, or in childbearing age and not willing to use contraception * Adult subject to a legal protection * Not covered by Health insurance * Patient unable to understand and sign written informed consent.
Where this trial is running
Montpellier, Hérault
- CHU de Montpellier — Montpellier, Hérault, France (Recruiting)
Study contacts
- Principal investigator: Thomas BARDOL, M.D. — University Hospital, Montpellier
- Study coordinator: Catherine ALIX-PANABIERES, Ph.D
- Email: c-panabieres@chu-montpellier.fr
- Phone: +33411759931
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.